The study focused on assessing whether Lumito’s labelling and imaging approach can be applied to cells captured using Tethis’ SmartBioSurface® slides, which are designed to enable rapid, gentle, and efficient adhesion of typically non-adherent cells. The proof-of-concept study yielded positive results, demonstrating feasibility and technical compatibility between Lumito’s technology and the Tethis slide platform.

This early collaboration shows that Lumito’s technology can be used in combination with Tethis’ slides, supporting the potential for integrated workflows in applications involving non-adherent cells.

“We are encouraged by the positive results from this initial study. Demonstrating that our UCNP-based labelling and imaging technology works together with Tethis’ SmartBioSurface slides is an important step in exploring how Lumito’s technology can be integrated into complementary platforms and workflows. Collaborations like this help broaden the potential application areas for our technology and strengthen the ecosystem around it”, says Sanna Wallenborg, CEO of Lumito.

“The results from this proof of concept are encouraging and confirm that Lumito’s advanced imaging approach can be applied on suspension cells captured using our SmartBioSurface slides. We see potential value in combining our slides that facilitate efficient cell capture and retention with highly sensitive biomarker detection, and we welcome further exploration of such integrated workflows”, says Holger Neecke, CEO of Tethis.

Next steps
Based on the positive outcome of the study, Lumito and Tethis plan to initiate joint marketing activities and establish a mutual referral approach. In parallel, an external researcher has expressed interest in evaluating the combined approach in more demanding applications. This represents an opportunity for further learning and validation of the technologies in advanced research settings.